Schistosoma Mansoni Infection, Susceptibility/ (SM1)

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Schistosoma Mansoni Infection, Susceptibility/

MalaCards integrated aliases for Schistosoma Mansoni Infection, Susceptibility/:

Name: Schistosoma Mansoni Infection, Susceptibility/ 56
Schistosoma Mansoni Infection, Susceptibility/resistance to 56 13
Schistosomiasis 58 71
Sm1 56 17
Schistosoma Mansoni, Intensity of Infection by; Sm1 56
Schistosoma Mansoni, Intensity of Infection by 56
Bilharziasis 58


Orphanet epidemiological data:

Inheritance: Not applicable; Age of onset: All ages;


autosomal dominant


schistosoma mansoni infection, susceptibility/:
Inheritance autosomal dominant inheritance


Orphanet: 58  
Rare infectious diseases

External Ids:

OMIM 56 181460
MESH via Orphanet 44 D012552
ICD10 via Orphanet 33 B65.0 B65.1 B65.2 more
UMLS via Orphanet 72 C0036323
Orphanet 58 ORPHA1247
MedGen 41 C1866993
SNOMED-CT via HPO 68 263681008
UMLS 71 C0036323

Summaries for Schistosoma Mansoni Infection, Susceptibility/

MalaCards based summary : Schistosoma Mansoni Infection, Susceptibility/, also known as schistosoma mansoni infection, susceptibility/resistance to, is related to intestinal schistosomiasis and urinary schistosomiasis. An important gene associated with Schistosoma Mansoni Infection, Susceptibility/ is SM1 (Schistosoma Mansoni, Susceptibility/Resistance To). The drugs Lumefantrine and Artemether have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and t cells, and related phenotype is abnormality of the immune system.

More information from OMIM: 181460

Related Diseases for Schistosoma Mansoni Infection, Susceptibility/

Diseases related to Schistosoma Mansoni Infection, Susceptibility/ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 573)
# Related Disease Score Top Affiliating Genes
1 intestinal schistosomiasis 12.9
2 urinary schistosomiasis 12.8
3 pulmonary arterial hypertension associated with schistosomiasis 12.4
4 cercarial dermatitis 12.2
5 neuroschistosomiasis 11.7
6 hepatic fibrosis, severe due to schistosoma mansoni infection 11.2
7 portal hypertension 10.9
8 splenomegaly 10.8
9 varicose veins 10.7
10 bladder cancer 10.7
11 hypereosinophilic syndrome 10.6
12 parasitic helminthiasis infectious disease 10.6
13 liver cirrhosis 10.6
14 esophageal varix 10.6
15 fibrosis of extraocular muscles, congenital, 1 10.6
16 pulmonary hypertension 10.5
17 allergic hypersensitivity disease 10.5
18 diarrhea 10.5
19 filariasis 10.5
20 malaria 10.4
21 hepatitis b 10.4
22 liver disease 10.4
23 appendicitis 10.4
24 fascioliasis 10.4
25 hepatitis c 10.4
26 small cell carcinoma 10.4
27 infertility 10.4
28 paragonimiasis 10.4
29 viral hepatitis 10.4
30 myelitis 10.4
31 pulmonary hypertension, primary, 1 10.4
32 ancylostomiasis 10.3
33 filarial elephantiasis 10.3
34 clonorchiasis 10.3
35 cytokine deficiency 10.3
36 hydronephrosis 10.3
37 onchocerciasis 10.3
38 hepatitis 10.3
39 glomerulonephritis 10.3
40 urinary tract obstruction 10.3
41 transverse myelitis 10.3
42 neuroblastoma 10.3
43 hepatocellular carcinoma 10.3
44 cystitis 10.3
45 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
46 kala-azar 1 10.3
47 salmonellosis 10.3
48 hypersplenism 10.3
49 leishmaniasis 10.3
50 hepatitis c virus 10.3

Graphical network of the top 20 diseases related to Schistosoma Mansoni Infection, Susceptibility/:

Diseases related to Schistosoma Mansoni Infection, Susceptibility/

Symptoms & Phenotypes for Schistosoma Mansoni Infection, Susceptibility/

Human phenotypes related to Schistosoma Mansoni Infection, Susceptibility/:

# Description HPO Frequency HPO Source Accession
1 abnormality of the immune system 31 HP:0002715

Symptoms via clinical synopsis from OMIM:

schistosoma mansoni infection susceptibility/resistance

Clinical features from OMIM:


Drugs & Therapeutics for Schistosoma Mansoni Infection, Susceptibility/

Drugs for Schistosoma Mansoni Infection, Susceptibility/ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Lumefantrine Approved Phase 4 82186-77-4 6437380
Artemether Approved Phase 4 71963-77-4 119380 68911
3 Artemether, Lumefantrine Drug Combination Phase 4
Myrrh Approved Phase 3 9000-45-7
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
Albendazole Approved, Vet_approved Phase 3 54965-21-8 2082
leucovorin Approved Phase 3 58-05-9 6006 143
Triclabendazole Approved, Investigational Phase 3 68786-66-3
Zinc Approved, Investigational Phase 2, Phase 3 7440-66-6 32051
Zinc sulfate Approved, Investigational Phase 2, Phase 3 7733-02-0
Mefloquine Approved, Investigational Phase 3 53230-10-7 4046
Artesunate Approved, Investigational Phase 3 88495-63-0 6917864 5464098
Amodiaquine Approved, Investigational Phase 3 86-42-0 2165
Tranexamic Acid Approved Phase 3 1197-18-8 5526
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
Piperaquine Experimental, Investigational Phase 3 4085-31-8 5079497
Dihydroartemisinin Experimental, Investigational Phase 3 71939-50-9 6918483
19 Iron Supplement Phase 3
20 Hematinics Phase 3
21 Ferric Compounds Phase 3
22 Fanasil, pyrimethamine drug combination Phase 3
23 Trace Elements Phase 2, Phase 3
24 Micronutrients Phase 2, Phase 3
25 Antimitotic Agents Phase 3
26 Renal Agents Phase 3
27 Folic Acid Antagonists Phase 3
28 Vitamin B Complex Phase 3
29 Folate Phase 3
30 Vitamin B9 Phase 3
31 Anti-Infective Agents, Urinary Phase 3
32 Sulfalene Phase 3
33 Nutrients Phase 2, Phase 3
34 Astringents Phase 2, Phase 3
35 Dermatologic Agents Phase 2, Phase 3
36 Antiprotozoal Agents Phase 3
37 Antimalarials Phase 3
38 Artemisinins Phase 3
39 Artemisinine Phase 3
40 Antiviral Agents Phase 3
41 Hemostatics Phase 3
42 Coagulants Phase 3
43 Antifibrinolytic Agents Phase 3
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2
Indian frankincense Approved, Experimental, Investigational Phase 1, Phase 2
Citric acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 77-92-9 311
Calcium Approved, Nutraceutical Phase 1, Phase 2 7440-70-2 271
Imidazole Experimental, Investigational Phase 1, Phase 2 288-32-4 795
Uric acid Investigational Phase 1, Phase 2 69-93-2 1175

Interventional clinical trials:

(show top 50) (show all 85)
# Name Status NCT ID Phase Drugs
1 The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
2 Effect of Schistosomiasis Mansoni and Its Treatment on HIV Susceptibility and Female Genital Immunology Completed NCT02878564 Phase 4 Praziquantel
3 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Highly Endemic Areas of Northeastern Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
4 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
5 Efficacy of Chinese-made Versus WHO-PQ Praziquantel for Treatment of Schistosoma Haematobium in Zanzibar: a Randomized Controlled Trial Unknown status NCT03133832 Phase 3 Companion Tablet
6 Intravenous Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania Unknown status NCT02541708 Phase 3 Ferric carboxymaltose;Ferrous sulfate + folic acid
7 Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire Completed NCT02868385 Phase 3 4x Praziquantel;1x Praziquantel
8 Safety and Efficacy of Mirazid for Schistosomiasis Treatment as Compared to Praziquantel: An Open-label Randomized Non-placebo-Controlled Study Completed NCT01529710 Phase 3 Myrrh
9 Schistosoma Haematobium Infections Among Schoolchildren in Central Sudan One Year After Treatment With Praziquantel Completed NCT01558336 Phase 3 praziquantel
10 Efficacy and Safety Evaluation of the Therapeutic Vaccine Candidate Sh28GST in Association With Praziquantel (PZQ) for Prevention of Clinical and Parasitological Recurrences of S. Haematobium Infection in Children Completed NCT00870649 Phase 3
11 Open-label, Randomized Clinical Trial in Kenya to Determine the Effectiveness of Artesunate + Sulfamethoxypyrazine/Pyrimethamine Vs. Praziquantel in the Treatment of S. Mansoni in Children Completed NCT01054651 Phase 3 Artesunate+Sulfamethoxypyrazine/pyrimethamine;Praziquantel
12 Efficacy and Safety of Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine Regimens Delivered Through Intermittent Preventive Treatment in Schoolchildren of Democratic Republic of Congo: A Randomised Control Trial Completed NCT01722539 Phase 3 Sulfadoxine-pyrimethamine;Piperaquine;Albendazole;Praziquantel
13 A Randomized, Double Blind, Controlled Study to Determine the Efficacy of Zinc Supplementation on Diarrhea Incidence in an Adult Population in Western Kenya. Completed NCT01166815 Phase 2, Phase 3
14 An Open Label, Phase III Efficacy and Safety Study of L Praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children 3 Months to 6 Years of Age, Including a 2:1 Randomized, Controlled Cohort of Schistosoma Mansoni Infected Children 4 to 6 Years of Age Treated With L PZQ ODT or Commercial PZQ (Biltricide®) Recruiting NCT03845140 Phase 3 L-PZQ ODT;Biltricide®;L-PZQ ODT
15 Prospective, Observational Study to Assess the Performance of CAA Measurement as a Diagnostic Tool for the Detection of Schistosoma Haematobium Infections in Pregnant Women and Their Newborn and Child in Lambaréné, Gabon Recruiting NCT03779347 Phase 3 Praziquantel
16 Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Recruiting NCT04115072 Phase 2, Phase 3 Praziquantel 600Mg Oral Tablet x 5;Praziquantel 600Mg Oral Tablet x 1
17 A Proof-of-concept Trial to Evaluate Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children Recruiting NCT03893097 Phase 3 Praziquantel;Artesunate + Mefloquine
18 Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania: A Controlled Randomised Trial Recruiting NCT03640403 Phase 3 Dihydroartemisinin-piperaquine;Artesunate-amodiaquine
19 Tranexamic Acid for the Treatment of Gastrointestinal Haemorrhage: an International Randomised, Double Blind Placebo Controlled Trial Recruiting NCT01658124 Phase 3 Tranexamic Acid;Placebo
20 Safety and Efficacy of a Novel Candidate Peptide Vaccine Against HCV Infection in Healthy Volunteers and in Treated (Non-responders/ Responders) Chronic HCV Patients. Clinical Trials Phases I and II Unknown status NCT01718834 Phase 1, Phase 2
21 Activity of Mefloquine Against Urinary Schistosomiasis Completed NCT01132248 Phase 2 Mefloquine;S/P
22 Intestinal Schistosomiasis in Children Aged 1-5 Years,Morbidity Assessment and the Effect of Praziquantel on Morbidity; Along Lake Victoria Shorelines. Completed NCT01901484 Phase 2 Praziquantel
23 Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 Against Schistosomiasis in Senegalese School Children Healthy or Infected With S. Mansoni and/or S. Haematobium. A Comparative, Randomized, Controlled, Open-label Trial Completed NCT03799510 Phase 2 GLA-SE solution
24 Open-label, Dose-finding, 2-parts, Efficacy Phase II Study With Three Formulations (Racemate Raziquantel Commercial Oral Tablets, New Oral Disintegrating Tablets of Racemate Praziquantel and L-praziquantel) in Schistosomiasis (S. Mansoni) Infected Children Aged 2-6 Years (Part 1), Followed by an Assessment of Efficacy and Safety With the Selected Formulation and Dosage in S. Mansoni Infected Infants Aged 3-24 Months (Part 2) Completed NCT02806232 Phase 2 Biltricide (racemate praziquantel) oral tablets;Racemate Praziquantel ODT;Levo Praziquantel ODT
25 S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT) Completed NCT00486863 Phase 2 Praziquantel
26 Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 in Combination With the Adjuvant Glucopyranosyl Lipid A (GLA-SE) in Adults Living in Endemic Regions for S. Mansoni and S. Haematobium in Senegal. A Comparative, Randomized, Open-label Trial Completed NCT03041766 Phase 2 GLA-SE solution
27 Phase II PK/PD Driven Dose Finding Trial of Praziquantel in Children Under Four Not yet recruiting NCT03640377 Phase 2 Praziquantel
28 A Phase I/II Trial of the Safety, Immunogenicity, and Efficacy of the Sm-TSP-2/Alhydrogel® Schistosomiasis Vaccine in Healthy Exposed Ugandan Adults Not yet recruiting NCT03910972 Phase 1, Phase 2
29 Treatment of Renal Stones With Frankincense (Boswellic Acid): A Clinical Randomized Trial Not yet recruiting NCT03924596 Phase 1, Phase 2 AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid);Potassium Sodium Hydrogen Citrate
30 Phase 1 Study Evaluating Safety and Immunological Criteria of Efficacy of the Recombinant Vaccine Candidate Bilhvax Against Schistosomiasis Completed NCT01512277 Phase 1
31 Praziquantel Pharmacokinetics in Pregnancy and During Lactation Completed NCT01288872 Phase 1 Praziquantel
32 Phase 1 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Completed NCT01154049 Phase 1
33 A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Completed NCT03110757 Phase 1
34 A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Completed NCT02337855 Phase 1
35 Group A Streptococcal Human Challenge Study: Building a Pharyngitis Model to Accelerate Vaccine Development Active, not recruiting NCT03361163 Phase 1
36 Association of Schistosomiasis Seropositivity With Adverse Birth Events in Migrants From Bilharzia-endemic Areas Unknown status NCT03158298
37 Study on the Role of Antioxidant Micronutrients on the Reversal of Schistosomal Peri-portal Fibrosis of the Liver. Unknown status NCT01260012
38 Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Among School Children in Jinja District, Uganda: a Stratified Cluster Randomized Controlled Trial Unknown status NCT01869465
39 The Evaluation of Glycyrrhizic Acid's Pesticide Effect in Treating Liver Damage (Retrospective Study) Unknown status NCT02329314
40 Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma Mansoni Co-infections and Its Impact on Anthelminthic Treatment Outcome Among HIV-1 Infected Individuals in Fishing Communities in Mwanza Region, Northwestern Tanzania. Unknown status NCT01541631 Praziquantel and Albendazole;Praziquantel and Albendazole;Praziquantel and Albendazole
41 ANRS 12320 IMMHoTHep : Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C Unknown status NCT02826447
42 Establishing a Single-sex Controlled Human Schistosomiasis Infection Model: Safety and Dose Finding Completed NCT02755324
43 Comparison of Schistosomiasis Diagnostic Techniques and Study of Schistosoma Infection on Children's Immune Response to Childhood Vaccines, on Anaemia and on Nutritional Status Completed NCT01553552
44 Effects of Arachidonic Acid Supplementation on Schistosomiasis Mansoni Infection in Egyptian School Children Completed NCT02144389 Praziquantel (PZQ)
45 Assessment of Anaemia Attributable to Schistosomiasis in School Children in Kenya: Mechanisms and Effect of Treatment Completed NCT00414479 praziquantl, iron, ACT
46 Evaluation of Applicability of Urine Based Schistosomiasis Test Strip in the Epidemiologic Mapping and Sampling of Schistosoma Mansoni Infection in Low Endemic Areas of Kenya Completed NCT00463307
47 Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Completed NCT00276224 ferrous sulphate (drug)
48 Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Completed NCT00463632
49 Health Benefits of Repeated Treatment in Pediatric Schistosomiasis Completed NCT01424410
50 Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment Completed NCT02495909

Search NIH Clinical Center for Schistosoma Mansoni Infection, Susceptibility/

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Genetic Tests for Schistosoma Mansoni Infection, Susceptibility/

Anatomical Context for Schistosoma Mansoni Infection, Susceptibility/

MalaCards organs/tissues related to Schistosoma Mansoni Infection, Susceptibility/:

Liver, Testes, T Cells, Colon, Spinal Cord, Skin, Spleen

Publications for Schistosoma Mansoni Infection, Susceptibility/

Articles related to Schistosoma Mansoni Infection, Susceptibility/:

(show top 50) (show all 15990)
# Title Authors PMID Year
Severe hepatic fibrosis in Schistosoma mansoni infection is controlled by a major locus that is closely linked to the interferon-gamma receptor gene. 61 56
10441577 1999
Absence of linkage between MHC and a gene involved in susceptibility to human schistosomiasis. 61 56
9698772 1998
Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. 61 56
8841190 1996
Evidence for the segregation of a major gene in human susceptibility/resistance to infection by Schistosoma mansoni. 61 56
1902058 1991
Schistosoma mansoni triggers Dectin-2, which activates the Nlrp3 inflammasome and alters adaptive immune responses. 56
21059925 2010
Schistosoma mansoni secretes a chemokine binding protein with antiinflammatory activity. 56
16301741 2005
Full results of the genome-wide scan which localises a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. 56
10094195 1999
Further evidence suggesting the presence of a locus, on human chromosome 5q31-q33, influencing the intensity of infection with Schistosoma mansoni. 56
9311752 1997
Assessment of dual schistosome infection prevalence from urine in an endemic community of Ghana by molecular diagnostic approach. 61
31930175 2020
Strongyloides venezuelensis-infection alters the profile of cytokines and liver inflammation in mice co-infected with Schistosoma mansoni. 61
31783260 2020
Schistosomiasis-associated pulmonary arterial hypertension: a systematic review. 61
32024722 2020
Biomphalaria glabrata immunity: Post-genome advances. 61
31759924 2020
Comparison of School-Based and Community-Wide Mass Drug Administration for Schistosomiasis Control in an Area of Western Kenya with High Initial Schistosoma mansoni Infection Prevalence: A Cluster Randomized Trial. 61
31802733 2020
The Journey to Discovering a Flatworm Target of Praziquantel: A Long TRP. 61
31787521 2020
Recent advances in Schistosoma mekongi ecology, transcriptomics and proteomics of relevance to snail control. 61
31669533 2020
Molecular Basis for Hycanthone Drug Action in Schistosome Parasites. 61
32027942 2020
Clinical and Preclinical Imaging of Hepatosplenic Schistosomiasis. 61
31864895 2020
Imported chronic schistosomiasis: screening and management issues. 61
31967311 2020
Schistosomiasis in children: review of 51 imported cases in Spain. 61
31821494 2020
Synthesis and Bioactivity of Phthalimide Analogs as Potential Drugs to Treat Schistosomiasis, a Neglected Disease of Poverty. 61
32028743 2020
Ectopic suicide inhibition of thioredoxin glutathione reductase. 61
31870799 2020
Schistosoma haematobium infection modulates Plasmodium falciparum parasite density and antimalarial antibody responses. 61
32020650 2020
Proteomic analysis of adult Schistosoma mekongi somatic and excretory-secretory proteins. 61
31672487 2020
(±)-Licarin A and its semi-synthetic derivatives: In vitro and in silico evaluation of trypanocidal and schistosomicidal activities. 61
31676458 2020
Effects of programmed cell death protein 10 on the Schistosoma japonicum female reproductive system. 61
31678234 2020
Diagnostic performance of two specific schistosoma japonicum immunological tests for screening schistosoma haematobium in school children in Zambia. 61
31786108 2020
Overcoming challenges in the diagnosis and treatment of parasitic infectious diseases in migrants. 61
31914335 2020
Role of the Pumilio gene in the reproductive system of Schistosoma japonicum. 61
31897787 2020
Comparative analysis of iTRAQ-based proteome profiles of Schistosoma japonicum female worms coming from single-sex infections and bisexual infections. 61
31778827 2020
Nontraumatic Myelopathy in Malawi: A Prospective Study in an Area with High HIV Prevalence. 61
31837130 2020
Morbidity and Mortality Due to Schistosoma mansoni Related Periportal Fibrosis: Could Early Diagnosis of Varices Improve the Outcome Following Available Treatment Modalities in Sub Saharan Africa? A Scoping Review. 61
32028581 2020
The Stakeholders' Views on Planting Trees to Control Schistosomiasis in China. 61
32028713 2020
Effect of a newly synthesized quinoline-based compound (PPQ-8) on murine schistosomiasis mansoni. 61
32029011 2020
Delay in schistosomiasis diagnosis and treatment: a multicenter cohort study in Italy. 61
31616948 2020
Through Biological Control to Reduce the Disease Burden of Human Schistosomiasis in Asia. 61
32013848 2020
Schistosomiasis, strongyloidiasis and Chagas disease: the leading imported neglected tropical diseases in Italy. 61
31840757 2020
Environmental Predictors of Schistosomiasis Persistent Hotspots following Mass Treatment with Praziquantel. 61
31889506 2020
Detection of Schistosoma DNA in genital specimens and urine: a comparison between five female African study populations originating from S. haematobium and/or S. mansoni endemic areas. 61
32035055 2020
Retraction Note: The epidemiology and chemotherapeutic approaches to the control of urinary schistosomiasis in school-age children (SAC): a systematic review. 61
32005106 2020
Urogenital schistosomiasis detected in sub-Saharan African migrants attending primary healthcare consultations in Paris, France: a 14-year retrospective cohort study (2004-2017). 61
32006177 2020
Focused Assessment with Sonography for Urinary Schistosomiasis (FASUS)-pilot evaluation of a simple point-of-care ultrasound protocol and short training program for detecting urinary tract morbidity in highly endemic settings. 61
31735956 2020
Follicular helper T cells recruit eosinophils into host liver by producing CXCL12 during Schistosoma japonicum infection. 61
31912645 2020
Rare cause of complicated Meckel's with Schistosoma infection: An unusual cause of acute intestinal obstruction in adults. 61
31877547 2020
Environmental arginine controls multinuclear giant cell metabolism and formation. 61
31969567 2020
Upregulation of KSRP by miR-27b attenuates schistosomiasis-induced hepatic fibrosis by targeting TGF-β1. 61
31953889 2020
Imported Schistosomiasis, China, 2010-2018. 61
31855529 2020
Changes in Morbidity, Physical Fitness, and Perceived Quality of Life among Schoolchildren following Four Years of Different Mass Drug Administration Strategies against Schistosoma mansoni Infection in Mwanza Region, Northwestern Tanzania. 61
31733051 2020
Screening and Phenotypical Characterization of Schistosoma mansoni Histone Deacetylase 8 (SmHDAC8) Inhibitors as Multistage Antischistosomal Agents. 61
31661956 2020
31978430 2020
Potassium usnate, a water-soluble usnic acid salt, shows enhanced activity against Schistosoma mansoni in vitro. 61
31634474 2020

Variations for Schistosoma Mansoni Infection, Susceptibility/

Expression for Schistosoma Mansoni Infection, Susceptibility/

Search GEO for disease gene expression data for Schistosoma Mansoni Infection, Susceptibility/.

Pathways for Schistosoma Mansoni Infection, Susceptibility/

GO Terms for Schistosoma Mansoni Infection, Susceptibility/

Sources for Schistosoma Mansoni Infection, Susceptibility/

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....